



# High Incidence of MDR and XDR *Pseudomonas aeruginosa* Isolates Harboring $bla_{GES}$ , $bla_{VEB}$ , and $bla_{PER}$ Extended-Spectrum Beta-Lactamase Genes in Iran

## ARTICLE INFO

### Article Type Original Article

### Authors

Fahimeh Beiki, MD<sup>1</sup>  
Amir Tavakoli Kareshk, PhD<sup>2,3</sup>  
Parvin Askari, PhD<sup>4</sup>  
Ali Hashemi, PhD<sup>5</sup>  
Masoud Yousefi, PhD<sup>6\*</sup>

### How to cite this article

Beiki F, Tavakoli Kareshk A, Askari P, Hashemi A, Yousefi M. High Incidence of MDR and XDR *Pseudomonas aeruginosa* Isolates Harboring  $bla_{GES}$ ,  $bla_{VEB}$ , and  $bla_{PER}$  Extended-Spectrum Beta-Lactamase Genes in Iran. *Infection Epidemiology and Microbiology*. 2022;8(4): 285-295.

<sup>1</sup> School of Medicine, Birjand University of Medical Sciences, Birjand, Iran.

<sup>2</sup> Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.

<sup>3</sup> Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran.

<sup>4</sup> Department of Medical Microbiology, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran.

<sup>5</sup> Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

<sup>6</sup> Department of Medical Microbiology, School of Medicine, Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.

### \* Correspondence

Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.  
E-mail: Masoud.yousefi@bums.ac.ir

### Article History

Received: June 14, 2022  
Accepted: November 04, 2022  
Published: December 19, 2022

## ABSTRACT

**Backgrounds:** The ever-increasing incidence of multidrug resistance in ESBL-producing *Pseudomonas aeruginosa* is one of the most serious public health threats. This study aimed to investigate the antibiotic resistance profile and molecular characteristics of ESBL-producing *P. aeruginosa* isolates.

**Materials & Methods:** Antimicrobial susceptibility testing was performed for 120 *P. aeruginosa* clinical isolates using the Kirby-Bauer disk diffusion and broth microdilution assays. Combined disk test (CDT) was applied to screen for ESBL production among *P. aeruginosa* isolates. PCR assays determined the presence of  $bla_{GES}$ ,  $bla_{PER}$ , and  $bla_{VEB}$  genes in all isolates.

**Findings:** The clinical isolates of *P. aeruginosa* showed the highest resistance to cefotaxime (86.7%) and gentamicin (65.8%). Of 120 *P. aeruginosa* isolates, 60.8% were MDR, and 53.3% were XDR. The prevalence of these strains was significantly higher in hospitalized patients than in out-patients ( $p < .001$ ). Also, 58 *P. aeruginosa* strains (48.3%) were considered as phenotypic ESBL producers. Furthermore, 15, 35, and 24.2% of *P. aeruginosa* isolates harbored  $bla_{GES}$ ,  $bla_{VEB}$ , and  $bla_{PER}$ , respectively. The incidence of MDR (71.4% vs. 41.9%,  $p = .001$ ) and XDR (63.6% vs. 34.9%,  $p = .002$ ) was significantly higher in ESBL-producing *P. aeruginosa* isolates compared to non-ESBL producers. The highest incidence rate of MDR was reported in  $bla_{VEB}$  gene-positive *P. aeruginosa* isolates (95.2%), followed by isolates harboring  $bla_{PER}$  (79.3%) and  $bla_{GES}$  (55.6%) genes.

**Conclusion:** This study findings show a high prevalence of MDR ESBL-producing *P. aeruginosa* isolates, indicating the importance of correct identification of these superbugs and judicious use of various antibiotics to prevent their spread.

**Keywords:** *Pseudomonas aeruginosa*, Drug resistance, Extended spectrum beta-lactamase, Beta-lactamase VEB, Beta-lactamase GES, Beta-lactamase PER.

## CITATION LINKS

- [1] Spagnolo AM, Sartini M, Cristina ML... [2] Pachori P, Gothalwal R, Gandhi P. ... [3] Sharifi H, Pouladfar G, Shakibaie MR, Pourabbas B, Mardaneh J, Mansouri S. Prevalence of  $\beta$ -lactamase genes, ... [4] Su TY, Ye JJ, Hsu PC, Wu HF, Chia JH, ... [5] Dehbashi S, Tahmasebi H, Arabestani MR. Association between... [6] Anvarinejad M, Japoni A, Rafaatpour N, Mardaneh J, Abbasi P, Shahidi MA, et al. Burn... [7] Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, et al. ... [8] Nazari-Alam A, Sarvari J, ... [9] Namaei MH, Yousefi M, Askari P, Roshanravan B, Hashemi A, Rezaei Y. High... [10] Askari P, Hakimi F, Moghanni M, Sebzari AR, Namaei MH. Evaluation... [11] Castanheira M, Simner PJ, Bradford PA. Extended-spectrum  $\beta$ -lactamases: An... [12] Laudy AE, Róg P, Smolińska-Król K, Ćmiel M, Słoczyńska A, Patzer J, et al. ... [13] Tawfik AF, Shibl AM, Aljohi MA, Altammami MA, Al-Agamy MH. Distribution of... [14] Libisch B, Poirel L, Lepsanovic Z, Mirovic V, Balogh B, Pászti J, et al. ... [15] Clinical and Laboratory... [16] Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas M, Giske C, et al. ... [17] Lee S, Park YJ, ... [18] Spilker T, Coenye T, Vandamme P, LiPuma JJ. ... [19] Gupta R, Malik A, Rizvi M, Ahmed M. Presence... [20] Farhan SM, Ibrahim RA, Mahran KM, ... [21] Chaudhary A, Bhandari D, ... [22] Porbaran M, Habibipour R. ... [23] Pérez A, Gato E, Pérez-Llarena J, Fernández-Cuenca F, ... [24] El-Far A, Samir S, ... [25] Ali FA, Bakir SH, Haji SH, Hussien BM. ... [26] Shukla SD, Gupta G, Khatoun R, Jain R, Gupta A. The rising threat of drug... [27] Del Giacomo P, Raffaelli F, Losito AR, ... [28] Vo T, Bui Q, Nguyen H, Pham H. ... [29] Mahto M, Shah A, Show K, ... [30] Moroh JL, Fleury Y, Tia H, Bahi C, Lietard C, ... [31] Hashemi NS, Mojiri M, ... [32] Sheikh AF, Shahin M, ... [33] Hosu MC, Vasaikar SD, Okuthe GE, Apalata T ... [34] Shiny P, Rajendran S, Sarayu YL. ... [35] Abdelrahman DN, Taha AA, ... [36] Afunwa RA, Odimegwu DC, Iroha RI, Esimone... [37] Shahcheraghi F, Nikbin VS, Feizabadi MM. ... [38] Haghighi S, Goli HR. High prevalence of bla VEB, bla GES, and... [39] Alikhani MY, Tabar ZK, ... [40] Komijani M, Shahin K, Barazandeh M, Sajadi M. ... [41] Shaikh S, Fatima J, ... [42] Shilpakar A, Ansari M, ... [43] Nasser M, Ogaili M, Palwe S, Kharat AS. Molecular detection of extended.

## Introduction

*Pseudomonas aeruginosa* is one of the most important infectious agents, especially in hospital wards. This opportunistic pathogen could survive on inanimate surfaces (including medical equipment), which causes the spread of this bacterium in hospital settings. Recently, the prevalence of *P. aeruginosa* infections has increased among hospitalized patients, particularly among those receiving extensive antibiotic treatment with long-term hospital stays [1-3].

In recent years, the widespread use of antibiotics has made bacteria resistant to broad-spectrum antibiotics of various antibiotic groups; thus, there are increasing reports of multiple drug resistant (MDR) strains. The ever-increasing incidence of antibiotic resistance among *P. aeruginosa* strains has become a worldwide health concern and resulted in severe adverse outcomes such as increased in-hospital mortality, cost, and hospital stay [4, 5]. Eradication of *P. aeruginosa* has become increasingly difficult due to its significant antibiotic resistance. For early detection and prevention of antibiotic resistance in *P. aeruginosa* and other pathogenic bacteria, continuous microbiological surveillance should be performed [6, 7].

In recent decades, beta-lactam antibiotics have been attractive in the treatment and prevention of infections caused by Gram-negative bacteria. Therefore, resistance to beta-lactam antibiotics is a serious challenge in the treatment of *P. aeruginosa* infections [8, 9]. The most important mechanism of resistance to beta-lactam antibiotics in Gram-negative bacteria is the production of beta-lactamase enzymes, especially extended-spectrum beta-lactamases (ESBLs) that confer resistance to most beta-lactam antibiotics, including penicillins, cephalosporins, and monobactam. The transmission of beta-lactamase genes between different bacterial strains could be accomplished

by highly diverse mobile genetic elements, which play a significant role in their rapid dissemination in hospital settings. ESBL-producing *P. aeruginosa* is one of the critical members of antibiotic-resistant bacteria whose spread in hospital environments could lead to the outbreak of infection and treatment failure [10, 11].

In the last decade, several classes of beta-lactamases (A, B, and D) were identified in *P. aeruginosa* strains. All ESBL-type enzymes belong to Ambler classes A and D. The most commonly encountered ESBLs in *P. aeruginosa* strains belong to the PER, GES, and VEB (class A) as well as OXA (class D) families. Moreover, the presence of ESBLs typical of the Enterobacteriaceae family, such as TEM, SHV, and CTX-M-type, has been described in a few *P. aeruginosa* isolates. GES-1 (Guiana extended-spectrum beta-lactamase) is the first member of the GES family, identified in *Klebsiella pneumoniae*. It exhibits strong activity against most beta-lactams and results in an ESBL phenotype. VEB (Vietnamese extended-spectrum beta-lactamase) and PER (*Pseudomonas* extended resistant) enzymes are frequently found in non-fermenting bacteria such as *P. aeruginosa*, and their abundance is increasing worldwide [12-14].

**Objectives:** Given the treatment failures of ESBL-producing *P. aeruginosa* infections worldwide and the importance of identifying and treating infections caused by these pathogens with high morbidity and mortality rates, this study aimed to evaluate the antibiotic resistance pattern and molecular characteristics of ESBL-producing *P. aeruginosa* isolates.

## Materials and Methods

**Study design:** This cross-sectional study was conducted on 120 non-duplicate *P. aeruginosa* clinical isolates collected from patients referring to Imam Reza hospital (60 isolates) in Birjand and the burn center

of Shahid Motahari hospital (60 isolates) in Tehran, Iran, from Jan 2018 to May 2019. Clinical samples collected from Imam Reza hospital in Birjand included urine, wound swab, blood, and lung secretion specimens, while those collected from the burn center of Shahid Motahari hospital in Tehran included only wound swab specimens. The Research Ethics Committee of Birjand University of Medical Sciences approved the study (IR.BUMS.REC.1397.198).

**Isolation and identification of *P. aeruginosa*:** All clinical samples were cultured on MacConkey agar (Merck, Germany) and 5% sheep blood agar (Merck, Germany) culture media, and then standard microbiological methods were employed to identify *P. aeruginosa* isolates (colony appearance, Gram stain, the alkaline reaction on Triple Sugar Iron [TSI] agar, oxidation/fermentation of glucose using OF media, growth at 42°C, motility, and oxidase test). Notably, the phenotypic identification of the isolates was confirmed by PCR and 16S rRNA gene sequencing using specifically targeted primers (Table 1).

**Antibiotic susceptibility testing (AST):** The antibiotic resistance pattern of the isolates was determined using the Kirby-Bauer disk-diffusion method according to Clinical and Laboratory Standards Institute (CLSI) guidelines [15]. The antibiotic disks (MAST,

UK) used for susceptibility testing in this study were Amikacin (30 µg), Aztreonam (30 µg), Piperacillin/tazobactam (100/10 µg), Cefotaxime (30 µg), Ceftazidime (30 µg), Cefepime (30 µg), Ciprofloxacin (5 µg), Gentamicin (10 µg), and Imipenem (10 µg). In addition, the minimum inhibitory concentration (MIC) for Colistin (Sigma-Aldrich, USA) was determined using the microdilution broth method. *P. aeruginosa* ATCC 27853 was used for quality control of antibiotic susceptibility testing. It should be noted that multidrug-resistant (MDR) and extensively drug-resistant (XDR) *P. aeruginosa* isolates were defined as those that were non-susceptible to at least one agent in three or more antimicrobial classes as well as those that were non-susceptible to at least one agent in all but two or fewer antimicrobial categories, respectively [16].

**Phenotypic detection of ESBL production:** ESBL production by *P. aeruginosa* isolates was detected using the combined disk test (CDT) method based on CLSI recommendations [15]. Briefly, the CDT phenotypic test was performed by comparing the inhibition zone diameter of disks containing cefotaxime (30 µg) and ceftazidime (30 µg) alone and in combination with clavulanic acid (30 µg/10 µg). An increase of 5 mm or more in the inhibition zone diameter was considered as an ESBL-positive isolate. *Escherichia coli*

**Table 1)** Target genes and their primers used in this study

Primer	Sequence (5'-3')	Products Sizes (bp)	Annealing (°C)	Ref.
<i>bla</i> <sub>GES</sub>	Fw- ATGCGCTTCATTACGCAC Rv- CTATTTGTCCGTGCTCAGG	864	50	[17]
<i>bla</i> <sub>VEB</sub>	Fw- CGACTTCCATTTCCCGATGC Rv- GGACTCTGCAACAAATACGC	643	60	[17]
<i>bla</i> <sub>PER</sub>	Fw- AATTTGGGCTTAGGGCAGAA Rv- ATGAATGTCATTATAAAAGC	925	53	[17]
16srRNA ( <i>P. aeruginosa</i> )	Fw- GGGGGATCTTCGGACCTCA Rv- TCCTTAGAGTGCCCCACCCG	956	58	[18]

ATCC 25922 was used as a negative control strain, and *K. pneumoniae* ATCC 700603 was used as a positive control strain.

**Genotypic detection of ESBL genes:** In the current study, the presence of *bla*<sub>GES</sub>, *bla*<sub>VEB</sub>, and *bla*<sub>PER</sub> genes responsible for ESBL production was investigated among all *P. aeruginosa* isolates using PCR assays based on specific primers shown in Table 1. DNA extraction was performed from *P. aeruginosa* clinical isolates using the High Pure PCR Template Preparation Kit (Roche, Germany) according to the manufacturer's instructions. PCR amplification was conducted in 25 µl volumes including 12.5 µl 2X Hot Star Taq Master Mix (Amplicon, Denmark), 1 µl forward and reverse primers (10 pmol/µl), 2 µl DNA, and 8.5 µl ddH<sub>2</sub>O using a thermocycler (PEQLAB, Erlangen, Germany). The reaction conditions were an initial denaturation at 94°C for 5 minutes; followed by 35 amplification cycles including denaturation at 94°C for 45 seconds, annealing at various temperatures for

different genes for 45 seconds (Table 1), and extension at 72°C for 45 seconds; and finally an additional extension step of 10 minutes at 72°C. PCR products were electrophoresed on 1% agarose gel containing DNA green viewer (Parstous, Iran).

**Statistical analysis:** The results related to antibiotic resistance pattern and ESBL production in the isolates were analyzed in SPSS statistical software (Version 21) using Pearson Chi-square and Fisher's exact tests with *p*-values of less than 0.05, which were regarded as statistically significant.

## Findings

**Patients and bacterial isolates:** In the present study, 120 non-repetitive *P. aeruginosa* clinical isolates were collected from two centers of Imam Reza hospital in Birjand and Shahid Motahari hospital in Tehran (60 isolates each). The majority of the isolates were isolated from wounds (69.2%, 83 isolates), followed by lung secretions (19.2%,

**Table 2)** Resistance pattern of *P. aeruginosa* isolates to different antimicrobial agents

Antimicrobial Agents	Resistance (%)	Intermediate (%)	Susceptible (%)
Piperacillin/tazobactam	67 (55.8)	4 (3.4)	49 (40.8)
Amikacin	68 (56.7)	1 (0.8)	51 (42.5)
Aztreonam	70 (58.3)	8 (6.7)	42 (35)
Ciprofloxacin	64 (53.3)	2 (1.7)	54 (45)
Gentamicin	79 (65.8)	2 (1.7)	39 (32.5)
Ceftazidime	71 (59.2)	1 (0.8)	48 (40)
Cefotaxime	104 (86.7)	2 (1.7)	14 (11.6)
Cefepime	69 (57.5)	2 (1.7)	49 (40.8)
Imipenem	63 (52.5)	1 (0.8)	56 (46.7)
Colistin	0 (0)	0 (0)	120 (100)
<b>MDR Status</b>			
Yes		73 (60.8)	
No		47 (39.2)	
<b>XDR Status</b>			
Yes		64 (53.3)	
No		56 (46.7)	

MDR: Multidrug-resistant, XDR: Extensively drug-resistant



**Table 3)** Distribution of MDR/XDR *P. aeruginosa* isolates by patient characteristics

Item/Status	<i>P. aeruginosa</i> Isolates		P-Value	<i>P. aeruginosa</i> Isolates		P-Value
	MDR (%)	Non-MDR (%)		XDR (%)	Non-XDR (%)	
Hospitalization Status						
In-patients	73 (67)	36 (33)	< .001	64 (58.7)	45 (41.3)	< .001
Out-patients	0 (0)	11 (100)		0 (0)	11 (100)	
Hospital Wards						
Surgery	2 (16.7)	10 (83.3)	< .001	0 (0)	12 (100)	< .001
Burn	67 (83.8)	13 (16.2)		61 (76.2)	19 (23.8)	
ICU	4 (23.5)	13 (76.5)		3 (17.7)	14 (82.3)	


MDR: Multidrug-resistant, XDR: Extensively drug-resistant

23 isolates), urine (10.8%, 13 isolates), and blood (0.8%, one isolate). Out of 120 *P. aeruginosa* isolates, 80 (66.7%) strains were isolated from males, and 40 (33.3%) strains were isolated from females. This study results showed that the mean age of patients was  $39.04 \pm 16.71$  years (ranging from 1 to 74 years), of which 109 (90.3%) cases were hospitalized patients (hospital stay >48 hours at the time of specimen collection), and 11 (9.7%) cases were out-patients.

**Antibiotic resistance pattern of *P. aeruginosa*:** The antibiotic resistance pattern of *P. aeruginosa* clinical isolates is shown in Table 2. The highest resistance of *P. aeruginosa* isolates was reported to be against cefotaxime (86.7%) and gentamicin (65.8%), while colistin and imipenem were the most effective antimicrobials with 100 and 46.7% susceptibility rates, respectively. The findings revealed that out of 120 *P. aeruginosa* isolates, 60.8% were multidrug-resistant (MDR), and 53.3% were extensively drug-resistant (XDR) (Table 2). Furthermore, the statistical analysis results indicated that MDR (67% vs. 0%,  $p < .001$ ) and XDR (58.7% vs. 0%,  $p < .001$ ) *P. aeruginosa* isolates were more prevalent in hospitalized patients than in out-patients. The prevalence of these MDR (83.8% vs. 23.5% in ICU and 16.7% in the surgical ward,  $p < .001$ ) and XDR (76.2% vs. 17.7% in ICU

and 0% in the surgical ward,  $p < .001$ ) isolates was significantly higher among patients admitted to the burn ward compared to other wards (Table 3).

**Distribution of phenotypic ESBL-producing *P. aeruginosa* and ESBL genes:** Out of a total of 120 *P. aeruginosa* isolates, 48.3% were considered as phenotypic ESBL producers. The results indicated that 15, 35, and 24.2% of *P. aeruginosa* isolates harbored  $bla_{GES}$ ,  $bla_{VEB}$ , and  $bla_{PER}$  genes, respectively (Figure 1). PCR amplification products of ESBL genes among *P. aeruginosa* isolates are shown in Figure 2.



**Figure 1)** Distribution of ESBL genes among *P. aeruginosa* isolates

**Distribution and antibiotic resistance pattern of ESBL-producing *P. aeruginosa*:** In this study, out of 77 *P. aeruginosa* iso-

**Table 4)** Distribution and antibiotic resistance of ESBL-producing *P. aeruginosa* isolates

Item/Status	<i>P. aeruginosa</i> Isolates		P-Value
	ESBL (%) (n=77)	Non-ESBL (%) (n=43)	
Hospitalization Status			
In-patients	71 (65.1)	38 (34.9)	.349
Out-patients	6 (54.5)	5 (45.5)	
Hospital Wards			
Surgery	8 (66.7)	4 (33.3)	.076
Burn	56 (70)	24 (30)	
ICU	7 (59.5)	10 (40.5)	
Multidrug-Resistant			
Yes	55 (71.4)	18 (41.9)	.001
No	22 (28.6)	25 (58.1)	
Extensively Drug-Resistant			
Yes	49 (63.6)	15 (34.9)	.002
No	28 (36.4)	28 (65.1)	

ESBL: Extended-spectrum beta-lactamase

**Table 5)** Antibiotic resistance pattern in *P. aeruginosa* isolates harboring different ESBL genes


	<i>P. aeruginosa</i> Harboring ESBL Genes		
	<i>bla</i> <sub>GES</sub> Positive (%) (n=18)	<i>bla</i> <sub>VEB</sub> Positive (%) (n=42)	<i>bla</i> <sub>PER</sub> Positive (%) (n=29)
Multidrug-Resistant			
Yes	10 (55.6)	40 (95.2)	23 (79.3)
No	8 (44.4)	2 (4.8)	6 (20.7)
Extensively Drug-Resistant			
Yes	9 (50)	36 (85.7)	20 (69)
No	9 (50)	6 (14.3)	29 (31)

lates that were phenotypically and/or genotypically ESBL-producers, 71.4 and 63.6% were MDR and XDR, respectively. The incidence of MDR (71.4% vs. 41.9%,  $p = .001$ ) and XDR (63.6% vs. 34.9%,  $p = .002$ ) was significantly higher among ESBL-producing *P. aeruginosa* isolates compared to non-ESBL producers. Furthermore, although the prevalence of ESBL-producing *P. aeruginosa*

isolates was higher in hospitalized patients than in out-patients (65.1% vs. 54.5%,  $p = .349$ ), especially among patients admitted to the burn ward compared to other wards (70% vs. 59.5% in ICU and 66.7% in the surgical ward,  $p = .076$ ), this difference was not significant (Table 4).

The highest incidence rate of MDR was reported in *bla*<sub>VEB</sub> gene-positive *P. aeruginosa*

isolates (95.2%), followed by isolates harboring *bla*<sub>PER</sub> (79.3%) and *bla*<sub>GES</sub> (55.6%) genes. Furthermore, the results indicated that 50, 85.7, and 69% of *P. aeruginosa* isolates carrying *bla*<sub>GES</sub>, *bla*<sub>VEB</sub>, and *bla*<sub>PER</sub> genes were XDR, respectively (Table 5).



**Figure 2)** PCR amplification products of ESBL genes in *P. aeruginosa* isolates. **(A)** PCR amplification of *bla*<sub>GES</sub> gene: Lane 1: DNA marker (100 bp), Lane 2 and 3: clinical isolates harboring *bla*<sub>GES</sub> gene (864 bp), and Lane 4: negative control. **(B)** PCR amplification of *bla*<sub>VEB</sub> gene: Lane 1: DNA marker (100 bp), Lane 2 and 3: clinical isolates harboring *bla*<sub>VEB</sub> gene (643 bp), and Lane 4: negative control. **(C)** PCR amplification of *bla*<sub>PER</sub> gene: Lane 1: DNA marker (100 bp), Lane 2 and 3: clinical isolates harboring *bla*<sub>PER</sub> gene (920 bp), and Lane 4: negative control

## Discussion

*P. aeruginosa* is one of the most important causes of nosocomial infections, and severe conditions caused by this pathogen are often life-threatening. The incidence of antibiotic resistance in *P. aeruginosa* strains is increasing, and identifying effective therapeutic options for managing MDR *P. aeruginosa* infections is still a challenge for physicians [4, 5, 13]. In this study, the highest resistance of 120 *P. aeruginosa* isolates was reported to be against cefotaxime (86.7%) and gentamicin (65.8%), while colistin and imipenem were the most effective antimicrobials with 100 and 46.7% susceptibility rates, respectively. Similar an-

timicrobial resistance patterns have been reported for *P. aeruginosa* in previous studies [19-21]. The ever-increasing incidence of antibiotic resistance in *P. aeruginosa* isolates has become a global health concern, especially in developing countries, which could be due to the relatively high level of over-the-counter antibiotic sales and frequent self-medication with antibiotics [19, 22].

The findings indicated that the prevalence rate of MDR and XDR *P. aeruginosa* isolates was 60.8 and 53.3%, respectively. Several studies have reported similar prevalence rates for MDR and XDR *P. aeruginosa* isolates [23-25]; however, a few studies have reported lower frequencies for MDR and XDR *P. aeruginosa* isolates [26-28]. This could be explained by differences in study populations, clinical sample type, geographic location, hospitalization status, hospital wards, and history of antibiotic use. Furthermore, the statistical analysis results indicated that MDR (67% vs. 0%,  $p < .001$ ) and XDR (58.7% vs. 0%,  $p < .001$ ) *P. aeruginosa* isolates were significantly more prevalent in hospitalized patients than in out-patients. The prevalence of these MDR/XDR isolates was considerably higher among patients admitted to the burn ward compared to other wards. In line with the present study findings, Mahto et al. (2021) also indicated that *P. aeruginosa* isolates obtained from inpatients were significantly more likely to be MDR/XDR than those obtained from out-patients [29]. In another study, the statistical analysis results showed that the incidence rate of MDR/XDR in uropathogenic bacteria (including *P. aeruginosa*), obtained from inpatients was significantly higher than in those obtained from out-patients [30]. In a study by Hashemi et al. (2017), resistance to most antibiotics was higher in *P. aeruginosa* isolates isolated from hospitalized patients compared to those isolated from out-patients [31]. In addition, Farajzadeh Sheikh et al. (2020) found that the prev-

alence of MDR *P. aeruginosa* isolates was higher among patients admitted to the burn ward compared to other wards [32]. It is noteworthy that the high prevalence of MDR and XDR *P. aeruginosa* isolates in hospitalized patients, especially in burn patients, is not unexpected due to long-term hospital stays and the use of various antibiotics to treat these patients.

The emergence and distribution of ESBL-producing *P. aeruginosa* strains represent a significant public health threat worldwide. ESBL-producing *P. aeruginosa* infections could lead to severe adverse clinical outcomes. Efforts to control the outbreak of these infections should emphasize prevention and management strategies and the judicious use of antimicrobial agents to reduce the spread of these resistant pathogens [10, 33]. In the current study, 48.3% of *P. aeruginosa* isolates were identified as phenotypic ESBL producers. In line with the present study, significant outbreaks of ESBL-producing *P. aeruginosa* infections have been reported in Saudi Arabia [13], Iraq [25], India [26, 34], Africa [33], Sudan [35], and Nigeria [36]. Furthermore, 15, 35, and 24.2% of *P. aeruginosa* isolates harbored  $bla_{GES}$ ,  $bla_{VEB}$ , and  $bla_{PER}$  respectively. Several studies have reported similar results regarding the distribution of ESBL genes in *P. aeruginosa* isolates with the predominance of the  $bla_{VEB}$  gene [13, 25, 37, 38]. In this study, the prevalence of MDR (71.4% vs. 41.9%,  $p = .001$ ) and XDR (63.6% vs. 34.9%,  $p = .002$ ) was significantly higher in ESBL-producing *P. aeruginosa* isolates compared to non-ESBL producers. Furthermore, the prevalence of ESBL-producing *P. aeruginosa* isolates was higher among hospitalized patients compared to out-patients as well as among patients admitted to the burn ward compared to other wards. Consistent with the present study results, Alikhani et al. (2014) also indicated that resistance to many antibiotics was higher in ESBL-positive *P. aeruginosa*

isolates than in ESBL-negative isolates [39]. Another study found a relatively high prevalence of MDR and ESBL production among *P. aeruginosa* isolates [40]. In a study by Shaikh et al. (2015), ESBL-producing *P. aeruginosa* isolates showed concomitant resistance to an array of antimicrobial agents [41]. In a previous study, the prevalence of ESBL-producing Gram-negative isolates, including *P. aeruginosa*, was significantly higher in hospitalized patients (21.2%) than in out-patients (15.3%) [42]. In another study, the highest prevalence of ESBL genes was observed in *P. aeruginosa* isolates collected from the burn ward, but no statistically significant relationship was observed in this regard [38]. The high frequency of MDR/XDR in ESBL-producing *P. aeruginosa* isolates indicates that these pathogens exhibit co-resistance to many antibiotic classes, which could lead to limited treatment options. Therefore, ESBL-related infections are increasing worldwide, and it is necessary to identify and control them in hospital settings. Finally, in this study, the highest incidence rate of MDR/XDR was reported in  $bla_{VEB}$  gene-positive *P. aeruginosa* isolates, followed by isolates harboring  $bla_{PER}$  and  $bla_{GES}$  genes. In a similar study, Shahcheraghi and colleagues (2009) showed that *P. aeruginosa* isolates containing  $bla_{VEB}$  were resistant to almost all antibiotics (except imipenem) compared to isolates positive for other ESBL genes [37]. In another study, resistance to most beta-lactam antibiotics was higher in  $bla_{VEB}$  gene-positive *P. aeruginosa* isolates than in isolates harboring  $bla_{PER}$  and  $bla_{GES}$  genes [38]. Moreover, Nasser et al. (2020) showed a high frequency of  $bla_{VEB}$  and  $bla_{GES}$  genes in MDR *P. aeruginosa* isolates compared to other ESBL genes [43]. The higher incidence of MDR in *P. aeruginosa* isolates harboring the  $bla_{VEB}$  gene may be explained by the fact that this gene is carried on plasmids containing other resistant genes. Overall, accurate tracking and reporting of ESBL-producing *P. aeruginosa* iso-



lates would help select appropriate treatment options and prevent further spread of these superbug pathogens.

### Conclusion

The present study findings show a high prevalence of MDR ESBL-producing *P. aeruginosa* isolates, indicating the importance of correct identification of these superbugs and judicious use of various antibiotics to prevent their spread. The results also show that colistin and imipenem are still effective antibiotics for the treatment of *P. aeruginosa* infection. The high prevalence of these resistant bugs reflects the need for more infection control surveillance and the establishment of effective antimicrobial stewardship programs in hospital settings.

### Acknowledgments

The authors would like to express their gratitude and thanks to the staff of microbiology laboratories of Imam Reza hospital in Birjand and the Shahid Motahari hospital in Tehran.

**Ethical permissions:** The Research Ethics Committee at Birjand University of Medical Sciences approved the study (IR.BUMS.REC.1397.198).

**Conflicts of interests:** The authors declare that they have no competing interests.

**Author's contributions:** FB and PK collected the data. ATK and AH collected the data, drafted the manuscript, and edited the paper. MY designed the study, collected the data, and revised the manuscript. All authors read and approved the final manuscript.

**Fundings:** This research was supported by Birjand University of Medical Sciences, Birjand, Iran (Grant Number 455695).

**Consent to participate:** Written informed consents were obtained from all patients.

### References

1. Spagnolo AM, Sartini M, Cristina ML. *Pseudomonas aeruginosa* in the healthcare facility setting.

- Rev Med Microbiol. 2021;32(3):169-75.
2. Pachori P, Gothwal R, Gandhi P. Emergence of antibiotic resistance *Pseudomonas aeruginosa* in intensive care unit: A critical review. *Genes Dis.* 2019;6(2):109-19.
  3. Sharifi H, Pouladfar G, Shakibaie MR, Pourabbas B, Mardaneh J, Mansouri S. Prevalence of  $\beta$ -lactamase genes, class 1 integrons, major virulence factors, and clonal relationships of multidrug-resistant *Pseudomonas aeruginosa* isolated from hospitalized patients in southeast of Iran. *Iran J Basic Med Sci.* 2019;22(7):806-12.
  4. Su TY, Ye JJ, Hsu PC, Wu HF, Chia JH, Lee MH. Clinical characteristics and risk factors for mortality in cefepime-resistant *Pseudomonas aeruginosa* bacteremia. *J Microbiol Immunol Infect.* 2015;48(2):175-82.
  5. Dehbashi S, Tahmasebi H, Arabestani MR. Association between beta-lactam antibiotic resistance and virulence factors in AmpC producing clinical strains of *P. aeruginosa*. *Osong Public Health Res Perspect.* 2018;9(6):325-33.
  6. Anvarinejad M, Japoni A, Razaatpour N, Mardaneh J, Abbasi P, Shahidi MA, et al. Burn patients infected with metallo-beta-lactamase-producing *Pseudomonas aeruginosa*: Multidrug-resistant strains. *Arch Trauma Res.* 2014;3(2):e18182.
  7. Lautenbach E, Synnestvedt M, Weiner MG, Bilkler WB, Vo L, Schein J, et al. Imipenem resistance in *Pseudomonas aeruginosa* emergence, epidemiology, and impact on clinical and economic outcomes. *Infect Control Hosp Epidemiol.* 2010;31(1):47-53.
  8. Nazari-Alam A, Sarvari J, Motamedifar M, Khoshkaram H, Yousefi M, Moniri R, et al. The occurrence of blaTEM, blaSHV, and blaOXA genotypes in extended-spectrum  $\beta$ -lactamase (ESBL)-producing *Pseudomonas aeruginosa* strains in southwest of Iran. *Gene Rep.* 2018;13:19-23.
  9. Namaei MH, Yousefi M, Askari P, Roshanravan B, Hashemi A, Rezaei Y. High prevalence of multidrug-resistant non-fermentative Gram-negative bacilli harboring blaIMP-1 and blaVIM-1 metallo-beta-lactamase genes in Birjand, south-east Iran. *Iran J Microbiol.* 2021;13(4):470-9.
  10. Askari P, Hakimi F, Moghanni M, Sebzari AR, Namaei MH. Evaluation of fecal colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae and risk factors among cancer patients in eastern Iran. *Infect Epidemiol Microbiol.* 2021;7(4):277-87.
  11. Castanheira M, Simner PJ, Bradford PA. Extended-spectrum  $\beta$ -lactamases: An update on their characteristics, epidemiology, and detection. *JAC Antimicrob Resist.* 2021;3(3):dlab092.
  12. Laudy AE, Róg P, Smolińska-Król K, Ćmiel M, Słoczyńska A, Patzer J, et al. Prevalence of ES-

- BL-producing *Pseudomonas aeruginosa* isolates in Warsaw, Poland, detected by various phenotypic and genotypic methods. *PloS One*. 2017;12(6):e0180121.
13. Tawfik AF, Shibl AM, Aljohi MA, Altammami MA, Al-Agamy MH. Distribution of Ambler class A, B, and D  $\beta$ -lactamases among *Pseudomonas aeruginosa* isolates. *Burns*. 2012;38(6):855-60.
  14. Libisch B, Poirel L, Lepsanovic Z, Mirovic V, Balogh B, Pászti J, et al. Identification of PER-1 extended-spectrum  $\beta$ -lactamase producing *Pseudomonas aeruginosa* clinical isolates of the international clonal complex CC11 from Hungary and Serbia. *FEMS Microbiol Immunol*. 2008;54(3):330-8.
  15. Clinical and Laboratory Standards Institute. CLSI supplement M100S: Performance standards for antimicrobial susceptibility testing. 29th Edition. Wayne PA: Clinical and Laboratory Standards Institute; 2019.
  16. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas M, Giske C, et al. Multidrug-resistant, extensively drug-resistant, and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012;18(3):268-81.
  17. Lee S, Park YJ, Kim M, Lee HK, Han K, Kang CS, et al. Prevalence of Ambler class A and D  $\beta$ -lactamases among clinical isolates of *Pseudomonas aeruginosa* in Korea. *J Antimicrob Chemother*. 2005;56(1):122-7.
  18. Spilker T, Coenye T, Vandamme P, LiPuma JJ. PCR-based assay for differentiation of *Pseudomonas aeruginosa* from other *Pseudomonas* species recovered from cystic fibrosis patients. *J Clin Microbiol*. 2004;42(5):2074-9.
  19. Gupta R, Malik A, Rizvi M, Ahmed M. Presence of metallo-beta-lactamases (MBL), extended-spectrum beta-lactamase (ESBL) & AmpC positive non-fermenting Gram-negative bacilli among intensive care unit patients with special reference to molecular detection of blaCTX-M & blaAmpC genes. *Indian J Med Res*. 2016;144(2):271-5.
  20. Farhan SM, Ibrahim RA, Mahran KM, Hetta HF, Abd El-Baky RM. Antimicrobial resistance pattern and molecular genetic distribution of metallo- $\beta$ -lactamases producing *Pseudomonas aeruginosa* isolated from hospitals in Minia, Egypt. *Infect Drug Resist*. 2019;12:2125-33.
  21. Chaudhary A, Bhandari D, Amatya J, Chaudhary P, Acharya B. Metallo-beta-lactamase producing Gram-negative bacteria among patients visiting Shahid Gangalal National Heart Centre. *Austin J Microbiol*. 2016;2(1):1010.
  22. Porbaran M, Habibipour R. Relationship between biofilm regulating operons and various  $\beta$ -lactamase enzymes: Analysis of the clinical features of infections caused by non-fermentative Gram-negative bacilli (NFGNB) from Iran. *J Pure Appl Microbiol*. 2020;14(3):1723-36.
  23. Pérez A, Gato E, Pérez-Llarena J, Fernández-Cuenca F, Gude MJ, Oviaño M, et al. High incidence of MDR and XDR *Pseudomonas aeruginosa* isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy, and Spain as part of the MagicBullet clinical trial. *J Antimicrob Chemother*. 2019;74(5):1244-52.
  24. El-Far A, Samir S, El-Gebaly E, Omar M, Dahroug H, El-Shenawy A, et al. High rates of aminoglycoside methyltransferases associated with metallo-beta-lactamases in multidrug-resistant and extensively drug-resistant *Pseudomonas aeruginosa* clinical isolates from a tertiary care hospital in Egypt. *Infect Drug Resist*. 2021;14:4849-58.
  25. Ali FA, Bakir SH, Haji SH, Hussen BM. Evaluation of blaGES-5 and bla veb-1 genes with multidrug-resistant extend, pandrug resistance patterns (MDR, XDR, PDR), and biofilm formation in *Pseudomonas aeruginosa* isolates. *Cell Mol Biol*. 2021;67(3):52-60.
  26. Shukla SD, Gupta G, Khatoon R, Jain R, Gupta A. The rising threat of drug resistant *Pseudomonas aeruginosa*: A nightmare for intensive care unit patients. *J Clin Diagn Res*. 2021;15(11):12-6.
  27. Del Giacomo P, Raffaelli F, Losito AR, Fiori B, Tumbarello M. XDR-*Pseudomonas aeruginosa* outside the ICU: Is there still place for colistin? *Antibiotics*. 2022;11(2):193.
  28. Vo T, Bui Q, Nguyen H, Pham H. Antimicrobial resistance patterns of *Pseudomonas aeruginosa* in a Vietnamese tertiary care hospital. *Int J Trop Dis*. 2022;5(1):058.
  29. Mahto M, Shah A, Show K, Moses F, Stewart A. *Pseudomonas aeruginosa* in Nepali hospitals: Poor outcomes amid 10 years of increasing antimicrobial resistance. *Public Health Action*. 2021;11(1):58-63.
  30. Moroh JL, Fleury Y, Tia H, Bahi C, Lietard C, Coroller L, et al. Diversity and antibiotic resistance of uropathogenic bacteria from Abidjan. *Afr J Urol*. 2014;20(1):18-24.
  31. Hashemi NS, Mojiri M, Yazdani Kachouyi P, Eskandari S, Mohammadian M, Alavi I. Prevalence of antibiotic resistance and blaIMP-1 gene among *Pseudomonas aeruginosa* strains isolated from burn and urinary tract infections in Isfahan, central Iran. *Microbiol Res*. 2017;8(2):59-63.
  32. Sheikh AF, Shahin M, Shokoohizadeh L, Ghanbari F, Solgi H, Shahcheraghi F. Emerge of NDM-1-producing multidrug-resistant *Pseudomonas aeruginosa* and co-harboring of carbapenemase genes in south of Iran. *Iran J Public Health*. 2020;49(5):959-67.
  33. Hosu MC, Vasaikar SD, Okuthe GE, Apalata T. De-

- tection of extended spectrum beta-lactamase genes in *Pseudomonas aeruginosa* isolated from patients in rural Eastern Cape province, South Africa. *Sci Rep.* 2021;11(1):1-8.
34. Shiny P, Rajendran S, Sarayu YL. A study on isolation and antibiotic sensitivity testing of *Pseudomonas aeruginosa* isolated from patients with respiratory tract infection with special reference to phenotypic and genotypic characterization of extended spectrum beta lactamases (ESBL). *Open J Med Microbiol.* 2016;6(2):80-6.
  35. Abdelrahman DN, Taha AA, Dafaallah MM, Mohammed AA, El Hussein AR, Hashim AI, et al.  $\beta$ -lactamases (bla TEM, bla SHV, bla CTXM-1, bla VEB, bla OXA-1) and class C  $\beta$ -lactamases gene frequency in *Pseudomonas aeruginosa* isolated from various clinical specimens in Khartoum State, Sudan: A cross sectional study. *F1000Res.* 2020;9:774.
  36. Afunwa RA, Odimegwu DC, Iroha RI, Esimone CO. Antimicrobial resistance status and prevalence rates of extended spectrum beta-lactamase producers isolated from a mixed human population. *Bosn J Basic Med Sci.* 2011;11(2):91-6.
  37. Shahcheraghi F, Nikbin VS, Feizabadi MM. Prevalence of ESBLs genes among multidrug-resistant isolates of *Pseudomonas aeruginosa* isolated from patients in Tehran. *Microb Drug Resist.* 2009;15(1):37-9.
  38. Haghighi S, Goli HR. High prevalence of bla VEB, bla GES, and bla PER genes in beta-lactam resistant clinical isolates of *Pseudomonas aeruginosa*. *AIMS Microbiol.* 2022;8(2):153-66.
  39. Alikhani MY, Tabar ZK, Mihani F, Kalantar E, Karami P, Sadeghi M, et al. Antimicrobial resistance patterns and prevalence of blaPER-1 and blaVEB-1 genes among ESBL-producing *Pseudomonas aeruginosa* isolates in west of Iran. *Jundishapur J Microbiol.* 2014;7(1):e8888.
  40. Komijani M, Shahin K, Barazandeh M, Sajadi M. Prevalence of extended-spectrum  $\beta$ -lactamases genes in clinical isolates of *Pseudomonas aeruginosa*. *Med. Lab J.* 2018;12(5):34-41.
  41. Shaikh S, Fatima J, Shakil S, Rizvi SM, Kamal MA. Prevalence of multidrug resistant and extended spectrum beta-lactamase producing *Pseudomonas aeruginosa* in a tertiary care hospital. *Saudi J Biol Sci.* 2015;22(1):62-4.
  42. Shilpakar A, Ansari M, Rai KR, Rai G, Rai SK. Prevalence of multidrug-resistant and extended-spectrum beta-lactamase producing Gram-negative isolates from clinical samples in a tertiary care hospital of Nepal. *Trop Med Health.* 2021;49(1):1-9.
  43. Nasser M, Ogaili M, Palwe S, Kharat AS. Molecular detection of extended spectrum  $\beta$ -lactamases, metallo  $\beta$ -lactamases, and Amp-C $\beta$ -lactamase genes expressed by multiple drug resistant *Pseudomonas aeruginosa* isolates collected from patients with burn/wound infections. *Burns Open.* 2020;4(4):160-6.